Virpax Pharmaceuticals Inc (VRPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) has a cash flow conversion efficiency ratio of 3.142x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($-913.76K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Virpax Pharmaceuticals Inc (VRPX) net asset quality to measure how much of total assets are equity-financed.
Virpax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Virpax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Virpax Pharmaceuticals Inc (VRPX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Virpax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virpax Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sino-German United AG
F:SGU
|
N/A |
|
PCI Biotech Holding ASA
OL:PCIB
|
-0.501x |
|
SMG EUROPEAN RECOV. EO 1
F:RCVR
|
N/A |
|
Global Gas Corporation
NASDAQ:HGAS
|
0.137x |
|
Europa Oil & Gas Holdings
LSE:EOG
|
-0.080x |
|
Baltic Bridge S.A.
WAR:WIS
|
N/A |
|
Water Ways Technologies Inc
V:WWT
|
0.002x |
|
VATIC VENTURES CORP.
F:V8V
|
0.002x |
Annual Cash Flow Conversion Efficiency for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Virpax Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see VRPX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-913.76 Million | $-16.71 Billion | 18.290x | +459.04% |
| 2023-12-31 | $1.93 Million | $-9.85 Million | -5.094x | -373.23% |
| 2022-12-31 | $16.58 Million | $-17.85 Million | -1.076x | -177.47% |
| 2021-12-31 | $37.48 Million | $-14.54 Million | -0.388x | -218.11% |
| 2020-12-31 | $-4.22 Million | $-1.38 Million | 0.328x | -20.71% |
| 2019-12-31 | $-2.73 Million | $-1.13 Million | 0.414x | -72.55% |
| 2018-12-31 | $-1.19 Million | $-1.80 Million | 1.509x | -- |
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more